Business
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and CEO of Xeris Biopharma, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00pm Eastern Time. A live webcast of the fireside chat will be available on the investor relations section of the Company's website at www.xerispharma.com.\n\nAbout Xeris Biopharma\n\nXeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient population in endocrinology, neurology, and gastroenterology. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.\n\nXeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220209005146/en/\n\nInvestor Contact\nAllison Wey\nSenior Vice President, Investor Relations and Corporate Communications\[email protected]\n\nSource: Xeris Biopharma Holdings","length":4168,"tagName":"div"}]